Proton Magnetic Resonance Spectroscopy

  • Z. Caramanos
  • A. C. Santos
  • S. J. Francis
  • S. Narayanan
  • D. Pelletier
  • D. L. Arnold
Part of the Topics in Neuroscience book series (TOPNEURO)


Approximately 85%-90% of patients with multiple sclerosis (MS) will begin their disease with a course of relapses and remissions and are therefore classified as having relapsing-remitting (RR) MS [1]. Some of these patients will eventually go on to develop a progressive disability that is characterized by a slow, irreversible deterioration over time, at which point they will be classified as having secondary progressive (SP) MS [1]. Interestingly, about 10%-15% of patients experience a progressive course, without any relapses or remissions, from the onset of their disease, and they are classified as having primary progressive (PP) MS [2].


Multiple Sclerosis Expand Disability Status Scale Proton Magnetic Resonance Spectroscopy Conventional Magnetic Resonance Imaging Expand Disability Status Scale Score 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907–911Google Scholar
  2. 2.
    Thompson AJ, Montalban X, Barkhof F et al (2000) Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 47:831–835PubMedCrossRefGoogle Scholar
  3. 3.
    Li DK, Zhao G, Paty DW (2000) T2 hyperintensities: findings and significance. Neuroimaging Clin N Am 10:717–738PubMedGoogle Scholar
  4. 4.
    Allen IV, McKeown SR (1979) A histological» histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci 41:81–91PubMedCrossRefGoogle Scholar
  5. 5.
    Allen IV, Glover G, Anderson R (1981) Abnormalities in the macroscopically normal white matter in cases of mild or spinal multiple sclerosis (MS). Acta Neuropathol Suppl (Berl) 7:176–178Google Scholar
  6. 6.
    Trapp BD, Peterson J, Ransohoff RM et al (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278–285PubMedCrossRefGoogle Scholar
  7. 7.
    Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452PubMedGoogle Scholar
  8. 8.
    Thompson AJ, Kermode AG, MacManus DG et al (1990) Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. Br Med J 300:631–634CrossRefGoogle Scholar
  9. 9.
    Stevenson VL, Miller DH, Rovaris M et al (1999) Primary and transitional progressive MS: a clinical and MRI cross-sectional study. Neurology 52:839–845PubMedGoogle Scholar
  10. 10.
    Thompson AJ, Kermode AG, MacManus DG et al (1989) Pathogenesis of progressive multiple sclerosis. Lancet 1:1322–1323PubMedCrossRefGoogle Scholar
  11. 11.
    Thompson AJ, Kermode AG, Wicks D et al (1991) Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 29:53–62PubMedCrossRefGoogle Scholar
  12. 12.
    Lycklama à Nijeholt GJ, van Walderveen MA, Castelijns JA et al (1998) Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. Brain 121:687–697Google Scholar
  13. 13.
    Leary SM, Davie CA, Parker GJ et al (1999) 1H magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis. J Neurol 246:1023–1026Google Scholar
  14. 14.
    Thompson AJ, Polman CH, Miller DH et al (1997) Primary progressive multiple sclerosis. Brain 120:1085–1096PubMedCrossRefGoogle Scholar
  15. 15.
    Arnold DL, De Stefano N, Narayanan S, Matthews PM (2000) Proton MR spectroscopy in multiple sclerosis. Neuroimaging Clin N Am 10:789–798PubMedGoogle Scholar
  16. 16.
    Ross B, Bluml S (2001) Magnetic resonance spectroscopy of the human brain. Anat Rec (New Anat) 265:54–84CrossRefGoogle Scholar
  17. 17.
    De Stefano N, Narayanan S, Francis GS et al (2001) Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 58:65–70PubMedCrossRefGoogle Scholar
  18. 18.
    Narayanan S, De Stefano N, Francis GS et al (2001) Axonal metabolic recovery in multiple sclerosis patients treated with interferon ß-1b. J Neurol 248:979–986PubMedCrossRefGoogle Scholar
  19. 19.
    Provencher SW (1993) Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30:672–679PubMedCrossRefGoogle Scholar
  20. 20.
    Christiansen P, Henriksen O, Stubgaard M et al (1993) In vivo quantification of brain metabolites by 1H-MRS using water as an internal standard. Magn Reson Imaging 11:107–118PubMedCrossRefGoogle Scholar
  21. 21.
    Pan JW, Twieg DB, Hetherington HP (1998) Quantitative spectroscopic imaging of the human brain. Magn Reson Med 40:363–369PubMedCrossRefGoogle Scholar
  22. 22.
    Urenjak J, Williams SR, Gadian DG, Noble M (1993) Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 13:981–989PubMedGoogle Scholar
  23. 23.
    Chang L, Ernst T, Osborn D et al (1998) Proton spectroscopy in myotonic dystrophy: correlations with CTG repeats. Arch Neurol 55:305–311PubMedCrossRefGoogle Scholar
  24. 24.
    De Stefano N, Matthews PM, Antel JP et al (1995) Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 38:901–909PubMedCrossRefGoogle Scholar
  25. 25.
    Helms G, Stawiarz L, Kivisakk P, Link H (2000) Regression analysis of metabolite concentrations estimated from localized proton MR spectra of active and chronic multiple sclerosis lesions. Magn Reson Med 43:102–110PubMedCrossRefGoogle Scholar
  26. 26.
    Sarchielli P, Presciutti O, Pelliccioli GP et al (1999) Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. Brain 122:513–521PubMedCrossRefGoogle Scholar
  27. 27.
    Simmons ML, Frondoza CG, Coyle JT (1991) Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 45:37–45PubMedCrossRefGoogle Scholar
  28. 28.
    Arnold DL, Matthews PM, Francis G, Antel J (1990) Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med 14:154–159PubMedCrossRefGoogle Scholar
  29. 29.
    Bitsch A, Bruhn H, Vougioukas V et al (1999) Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol 20:1619–1627PubMedGoogle Scholar
  30. 30.
    Arnold DL, Matthews PM, Francis GS et al (1992) Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol 31:235–241PubMedCrossRefGoogle Scholar
  31. 31.
    Nicoli F, Vion-Dury J, Confort-Gouny S et al (1996) Cerebrospinal fluid metabolic profiles in multiple sclerosis and degenerative dementias obtained by high resolution proton magnetic resonance spectroscopy. C R Acad Sci III 319:623–631Google Scholar
  32. 32.
    Davie CA, Barker GJ, Thompson AJ et al (1997) 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry 63:736–742PubMedCrossRefGoogle Scholar
  33. 33.
    Pan JW, Whitaker JN (1998) Quantitation of 1H metabolites in subtypes of multiple sclerosis by spectroscopic imaging at 4.1 T [abstract]. Proc Int Soc Magn Reson Med 1:428Google Scholar
  34. 34.
    Pike GB, de Stefano N, Narayanan S et al (1999) Combined magnetization transfer and proton spectroscopic imaging in the assessment of pathologic brain lesions in multiple sclerosis. AJNR Am J Neuroradiol 20:829–837PubMedGoogle Scholar
  35. 35.
    Cucurella MG, Rovira A, Rio J et al (2000) Proton magnetic resonance spectroscopy in primary and secondary progressive multiple sclerosis. NMR Biomed 13:57–63PubMedCrossRefGoogle Scholar
  36. 36.
    Pan JW, Krupp LB, Elkins L, Coyle PK (2000) Cognitive dysfunction lateralizes with NAA in multiple sclerosis [abstract]. Proc Intl Soc Magn Reson Med 1:296Google Scholar
  37. 37.
    Suhy J, Rooney WD, Goodkin DE et al (2000) 1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS. Mult Scler 6:148–155PubMedGoogle Scholar
  38. 38.
    Oh J, Pelletier D, Nelson SJ (2001) Proton magnetic resonance spectroscopy in assessing axonal loss in the corpus callosum related with volume of regional T1 lesion load in multiple sclerosis [abstract]. Proc Int Soc Mag Reson Med 2:471Google Scholar
  39. 39.
    Pelletier D, Grenier D, Lu Y et al (2001) Regional comparison of axonal damage in multiple sclerosis using whole supratentorial brain 3D spectroscopy imaging [abstract], Proc Int Soc Magn Reson Med 2:985Google Scholar
  40. 40.
    Pelletier D, Grenier D, Antel JP et al (2001) MRI lesion volume heterogeneity in primary progressive multiple sclerosis: an assessment of axonal damage and brain atrophy measurement [abstract]. Neurology 56:A380Google Scholar
  41. 41.
    Viala K, Stievenart JL, Cabanis EA et al (2001) Study with localized proton magnetic resonance spectroscopy of 31 multiple sclerosis lesions: correlations with clinical and MRI features (in French). Rev Neurol (Paris) 157:35–44Google Scholar
  42. 42.
    Gonen O, Catalaa I, Babb JS et al (2000) Total brain N-acetylaspartate: a new measure of disease load in MS. Neurology 54:15–19PubMedGoogle Scholar
  43. 43.
    Posse S, DeCarli C, Le Bihan D (1994) Three-dimensional echo-planar MR spectroscopic imaging at short echo times in the human brain. Radiology 192:733–738PubMedGoogle Scholar
  44. 44.
    Van den Boogaart A, Vanhamme L (1997) MRUI Manual v. 96.3. A User’s Guide to the Magnetic Resonance User Interface software package. Delft Technische Universiteit Press, DelftGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 2002

Authors and Affiliations

  • Z. Caramanos
  • A. C. Santos
  • S. J. Francis
  • S. Narayanan
  • D. Pelletier
  • D. L. Arnold

There are no affiliations available

Personalised recommendations